HUM vs. TAK: A Head-to-Head Stock Comparison

Updated on August 18, 2025

Here’s a clear look at HUM and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

HUM is a standard domestic listing, while TAK trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

Symbol	HUM	TAK
Company Name	Humana Inc.	Takeda Pharmaceutical Company Limited
Country	United States	Japan
GICS Sector	Health Care	Health Care
GICS Industry	Health Care Providers & Services	Pharmaceuticals
Market Capitalization	33.92 billion USD	46.65 billion USD
Exchange	NYSE	NYSE
Listing Date	December 31, 1981	January 5, 2010
Security Type	Common Stock	ADR

Historical Performance

This chart compares the performance of HUM and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

HUM vs. TAK: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	HUM	TAK
5-Day Price Return	10.09%	2.78%
13-Week Price Return	11.52%	5.93%
26-Week Price Return	0.86%	5.75%
52-Week Price Return	-19.04%	5.51%
Month-to-Date Return	12.85%	3.74%
Year-to-Date Return	11.15%	4.21%
10-Day Avg. Volume	1.73M	5.48M
3-Month Avg. Volume	1.86M	4.67M
3-Month Volatility	47.01%	15.38%
Beta	0.46	0.42

Profitability

Return on Equity (TTM)

HUM

9.02%

Health Care Providers & Services Industry

Max: 26.03%
Q3: 13.74%
Median: 8.26%
Q1: 4.13%
Min: -3.62%

HUM’s Return on Equity of 9.02% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.

TAK

1.48%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

TAK’s Return on Equity of 1.48% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.

HUM vs. TAK: A comparison of their Return on Equity (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

HUM

1.28%

Health Care Providers & Services Industry

Max: 12.40%
Q3: 5.93%
Median: 1.96%
Q1: 0.93%
Min: -6.10%

HUM’s Net Profit Margin of 1.28% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

TAK

2.36%

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 2.36% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

HUM vs. TAK: A comparison of their Net Profit Margin (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

HUM

2.68%

Health Care Providers & Services Industry

Max: 19.05%
Q3: 10.21%
Median: 4.22%
Q1: 1.98%
Min: -4.27%

HUM’s Operating Profit Margin of 2.68% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

TAK

7.48%

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

TAK’s Operating Profit Margin of 7.48% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

HUM vs. TAK: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	HUM	TAK
Return on Equity (TTM)	9.02%	1.48%
Return on Assets (TTM)	3.19%	0.72%
Net Profit Margin (TTM)	1.28%	2.36%
Operating Profit Margin (TTM)	2.68%	7.48%
Gross Profit Margin (TTM)	--	65.51%

Financial Strength

Current Ratio (MRQ)

HUM

0.01

Health Care Providers & Services Industry

Max: 2.01
Q3: 1.49
Median: 1.30
Q1: 0.94
Min: 0.17

HUM’s Current Ratio of 0.01 is notably low, falling beneath the typical range for the Health Care Providers & Services industry. This suggests a heightened liquidity risk and could indicate potential challenges in meeting its short-term obligations.

TAK

1.01

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

TAK’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

HUM vs. TAK: A comparison of their Current Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

HUM

0.69

Health Care Providers & Services Industry

Max: 2.17
Q3: 1.18
Median: 0.74
Q1: 0.45
Min: 0.00

HUM’s Debt-to-Equity Ratio of 0.69 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

TAK

0.65

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

TAK’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

HUM vs. TAK: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

HUM

3.61

Health Care Providers & Services Industry

Max: 14.47
Q3: 7.15
Median: 5.45
Q1: 2.04
Min: -4.44

HUM’s Interest Coverage Ratio of 3.61 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.

TAK

2.05

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 2.05 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

HUM vs. TAK: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	HUM	TAK
Current Ratio (MRQ)	0.01	1.01
Quick Ratio (MRQ)	0.01	0.52
Debt-to-Equity Ratio (MRQ)	0.69	0.65
Interest Coverage Ratio (TTM)	3.61	2.05

Growth

Revenue Growth

HUM vs. TAK: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

HUM vs. TAK: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

HUM

1.28%

Health Care Providers & Services Industry

Max: 5.38%
Q3: 2.22%
Median: 0.55%
Q1: 0.00%
Min: 0.00%

HUM’s Dividend Yield of 1.28% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.

TAK

4.39%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

With a Dividend Yield of 4.39%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

HUM vs. TAK: A comparison of their Dividend Yield (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

HUM

14.15%

Health Care Providers & Services Industry

Max: 186.69%
Q3: 74.82%
Median: 26.76%
Q1: 0.00%
Min: 0.00%

HUM’s Dividend Payout Ratio of 14.15% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

TAK

138.69%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

TAK’s Dividend Payout Ratio of 138.69% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

HUM vs. TAK: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	HUM	TAK
Dividend Yield (TTM)	1.28%	4.39%
Dividend Payout Ratio (TTM)	14.15%	138.69%

Valuation

Price-to-Earnings Ratio (TTM)

HUM

21.32

Health Care Providers & Services Industry

Max: 55.89
Q3: 30.85
Median: 21.17
Q1: 12.63
Min: 0.00

HUM’s P/E Ratio of 21.32 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

TAK

63.81

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

At 63.81, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

HUM vs. TAK: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

HUM

0.27

Health Care Providers & Services Industry

Max: 3.10
Q3: 1.74
Median: 0.67
Q1: 0.24
Min: 0.00

HUM’s P/S Ratio of 0.27 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

TAK

1.50

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

In the lower quartile for the Pharmaceuticals industry, TAK’s P/S Ratio of 1.50 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

HUM vs. TAK: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

HUM

1.62

Health Care Providers & Services Industry

Max: 7.61
Q3: 4.32
Median: 2.53
Q1: 1.14
Min: 0.77

HUM’s P/B Ratio of 1.62 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

TAK

1.01

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

TAK’s P/B Ratio of 1.01 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

HUM vs. TAK: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	HUM	TAK
Price-to-Earnings Ratio (TTM)	21.32	63.81
Price-to-Sales Ratio (TTM)	0.27	1.50
Price-to-Book Ratio (MRQ)	1.62	1.01
Price-to-Free Cash Flow Ratio (TTM)	10.77	9.71